Helix BioPharma Corp. announced the voting results of the Company's annual and special meeting of shareholders held on January 28, 2022. In aaccordance with section11.3 of National Instrument 51-102 Continuous Disclosure Obligations, and the appointment of Mr. Adam Uszpolewicz to company's Board of Directors.

Mr. Uszpolewicz brings 30 years of professional experience working in varied financial services sectors, including life, health and general insurance, asset management, pensions, banking and management consulting, and has significant experience leading M&A transactions.